National Institute on Drug Abuse (NIDA): Opioid-Related Disorders trials

The registry lists 74 Opioid-Related Disorders studies with National Institute on Drug Abuse (NIDA) as lead sponsor. 4 are open to participants now and 2 have results posted.

Phase 1 25Phase 2 37Phase 3 2Phase 4 1No phase 12(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Phase 1 Study of Oral MG001Not yet recruitingNCT07204171Phase 1
• VK4-116 Phase I Study With Food-EffectNot yet recruitingNCT06808932Phase 1
• Evaluation of the Interactions of Cannabidiol (CBD) With MorphineRecruitingNCT05143424Phase 1
• Outcome Inference in the Sensory Preconditioning Task in Opioid-Use DisorderRecruitingNCT03745339
• Biased Opioid Agonists for Treatment of Opioid Withdrawal in OUDTerminatedNCT04316559Phase 2Results posted
• The Discriminative Effects of Tramadol in HumansCompletedNCT00499746Phase 1/2Results posted
• Measuring the Effects of Neurostimulation on Risky and Ambiguous Decision-Making Capacity in People With and Without Substance Use DisorderSuspendedNCT06577454Not applicable
• Evaluation of Intranasal Naltrexone and NaloxoneCompletedNCT03851731Phase 1
• Imaging Biomarker for Addiction Treatment OutcomeTerminatedNCT03427424
• Comparison of Naloxone PharmacokineticsCompletedNCT03386591Phase 1
• Pharmacokinetic Evaluation of Nalmefene Administered Intranasally to Healthy VolunteersCompletedNCT03129347Phase 1
• Pharmacokinetic Evaluation of Intranasal, Intramuscular, and Oral Naltrexone in Healthy VolunteersCompletedNCT02750748Phase 1
• Pharmacokinetic Evaluation of Intranasal and Intramuscular Naloxone in Healthy VolunteersCompletedNCT02572089Phase 1
• Pioglitazone to Treat Opioid Withdrawal SymptomsTerminatedNCT01517165Phase 1
• Aripiprazole for Prevention of Relapse to Cocaine Use in Methadone-Maintenance PatientsCompletedNCT00780702Phase 1
• Clonidine for Relapse Prevention in Buprenorphine-Maintenance PatientsCompletedNCT00295308Phase 1
• Real Time Assessment of Drug Craving, Use, and Abstinence During Outpatient: A Development and Feasibility StudyCompletedNCT00292136
• Combined Behavioral and Pharmacologic Treatment of Polydrug AbuseCompletedNCT00292123Phase 1
• Medication Adherence Therapy for Opioid Abusing Pain PatientsCompletedNCT00249587Phase 1/2
• Dextromethorphan, Gabapentin, and Oxycodone to Treat Opioid-Induced HyperalgesiaCompletedNCT00218374Not applicable
• Effects of Pre-Session Supplemental Hydromorphone on Drug Seeking Behavior in Opioid Dependent IndividualsCompletedNCT00218309
• Treatment of Opioid/Heroin Dependence: Comparison of Three Medication Dosing RegimensCompletedNCT00218127Phase 2
• Buprenorphine as a Treatment for Individuals Dependent on Analgesic OpioidsCompletedNCT00218101Phase 2
• Methadone Levels in Breast Milk of Women Taking Methadone for Opiate Addiction - 2CompletedNCT00218010
• The Efficacy of Methadyl Acetate (LAAM) and Contingency Management Procedures for Treating Dual Opioid and Cocaine Abuse - 1CompletedNCT00158288Phase 2
• Abuse Potential of Buprenorphine and Naloxone in Non-Dependent Opioid UsersCompletedNCT00158236Not applicable
• Abuse Potential of Buprenorphine/NaloxoneTerminatedNCT00149539Phase 2
• Tramadol to Reduce Opioid Withdrawal SymptomsCompletedNCT00142896Phase 2
• Fluoxetine to Reduce Cocaine Use in Cocaine and Opioid AddictsCompletedNCT00142779Not applicable
• Opioid Agonist and Antagonist Effects on Opioid DependenceTerminatedNCT00142727Phase 2
• Addition of Naltrexone to Methadone TaperCompletedNCT00135759Phase 2
• Effects of Buprenorphine/Naloxone Administered in Different Ways For Treating Opioid DependenceCompletedNCT00134914Not applicable
• Blockade Efficacy of Buprenorphine/Naloxone For Opioid DependenceCompletedNCT00134888Not applicable
• Effectiveness of Tiagabine for Cocaine Dependence in Methadone-Maintained Individuals - 1CompletedNCT00129298Phase 2
• Lofexidine for Opiate Withdrawal - 1CompletedNCT00032942Phase 3
• Buprenorphine/Naloxone in the Treatment of Heroin Dependence - 14CompletedNCT00015340Phase 4
• Buprenorphine and Naloxone Combination Study - 10CompletedNCT00015288Phase 1
• Buprenorphine and Naloxone for the Treatment of Opiate Dependence - 1CompletedNCT00015171Phase 3
• Buprenorphine Dose Escalation Trial for Treatment of Non-Dependent Opiate Users - 2CompletedNCT00015041Phase 1
• Buprenorphine/Naloxone for Opiate-Dependence Treatment - 1CompletedNCT00015028Phase 2
• Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 7CompletedNCT00000358Phase 1
• Buprenorphine Maintenance for Opiate Dependence - 6CompletedNCT00000357Phase 2
• Evaluation of L-alpha-acetylmethadol (LAAM) in Methadone Patients - 5CompletedNCT00000356Phase 2
• Effects of Buprenorphine and Naloxone in Opiate Addicts - 4CompletedNCT00000355Phase 1
• Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 3CompletedNCT00000354Phase 1
• Trial of Buprenorphine/Naloxone for Opiate Dependence - 2CompletedNCT00000353Phase 2
• Effects of Dextromethorphan on Opioid Tolerance in Methadone Patients - 1CompletedNCT00000352Phase 2
• Evaluation of Lofexidine for Treatment of Opiate Withdrawal - 10CompletedNCT00000345Phase 1
• Buprenorphine/Naloxone for Treatment of Opiate Dependence - 9CompletedNCT00000344Phase 2
• Evaluation of Liquid vs. Tablet Buprenorphine - 6CompletedNCT00000341Phase 2
• Activity Monitoring Assessment of Opiate Withdrawal - 4CompletedNCT00000335Phase 2
• Comparison of Buprenorphine and Methadone - 3CompletedNCT00000334Phase 2
• Buprenorphine Formulation Comparison: Sublingual Tablet vs. Solution - 1CompletedNCT00000320Phase 1/2
• Buprenorphine Maintenance Dose Schedule and Treatment Setting - 1CompletedNCT00000318Phase 2
• Dextroamphetamine as Adjunct in Cocaine/Opiate Dependent Patients - 3CompletedNCT00000306Phase 2
• Buprenorphine Combination Tablet Feasibility - 1CompletedNCT00000298Phase 2
• Effects of Buprenorphine/Naloxone in Treating Opioid Dependent Individuals Who Are Maintained on MethadoneTerminatedNCT00000243Not applicable
• Buprenorphine Pharmacology Related to Addiction Treatment - 21CompletedNCT00000239Phase 2
• Temporal Discounting Delayed Outcomes on Opioid-Dependent Outpatients - 20CompletedNCT00000238Phase 2
• Buprenorphine Detoxification - BBDVI - 19CompletedNCT00000237Phase 2
• Buprenorphine Pharmacology Related to Addiction Treatment - 18CompletedNCT00000236Phase 2
• Alternate Day Buprenorphine Administration, Phase XII - 17CompletedNCT00000235Phase 2
• Alternate Day Buprenorphine Administration, Phase X - 15CompletedNCT00000233Phase 2
• Buprenorphine Detoxification With Two Types of Treatment. BBD IV - 13CompletedNCT00000231Phase 2
• Buprenorphine Detox With Two Types of Treatment. BBD I - 10CompletedNCT00000228Phase 2
• Alternate-Day Buprenorphine Administration. Phase VII - 8CompletedNCT00000226Phase 2
• Alternate-Day Buprenorphine Administration. Phase VI - 7CompletedNCT00000225Phase 2
• Alternate-Day Buprenorphine. Phase V - 6CompletedNCT00000224Phase 1
• Alternate-Day Buprenorphine Administration. Phase IV - 5CompletedNCT00000223Phase 2
• Alternate-Day Buprenorphine Administration. Phase II - 4CompletedNCT00000222Phase 1
• Alternate-Day Buprenorphine Administration. Phase I - 3CompletedNCT00000221Phase 1
• Gradual Vs. Rapid Buprenorphine Detoxification - 2CompletedNCT00000220Phase 1
• Buprenorphine Dosing Interval - 5CompletedNCT00000209Phase 2
• Methadone/Buprenorphine Cross-Over Study - 4CompletedNCT00000208Phase 2